Literature DB >> 27604832

Is there an association between prior anti-inflammatory drug exposure and occurrence of peritonsillar abscess (PTA)? A national multicenter prospective observational case-control study.

D Lepelletier1,2, V Pinaud3, P Le Conte3, C Bourigault4, N Asseray5,6, F Ballereau7,6, J Caillon4,6, C Ferron8, C Righini9, E Batard3,6, G Potel3,6.   

Abstract

The aim of this study was to evaluate whether recent systemic anti-inflammatory agents (AIAs) exposure in patients with sore throat managed with or without antibiotic therapy influenced the risk of peritonsillar abscess (PTA). We conducted a multicenter case-control study in 13 French university hospitals in 2009-2012 comparing patients admitted with PTA to matched controls: patients with sore throat but without PTA who were followed up for 10 days after visiting their primary-care physician. In the multivariate stepwise logistic regression model comparing 120 cases with PTA to 143 controls, factors significantly associated with PTA were male gender (odds ratio [OR], 2.0; p = 0.03), smoking (OR, 2.0; p = 0.03), and prior self-medication with systemic AIAs (OR, 3.5; p = 0.01). Topical treatment was associated with significant protection against PTA (OR, 0.3; p < 0.001). In conclusion, self-medication with systemic AIAs appears to be an independent factor associated with the occurrence of PTA. This is an important message as non-steroidal AIAs access is favored by their over-counter availability in pharmacies. This finding must be interpreted with caution due to the study design and a prospective, randomized study is needed to substantiate these possible causal risk factors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27604832     DOI: 10.1007/s10096-016-2770-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  17 in total

1.  Selection of controls in case-control studies. II. Types of controls.

Authors:  S Wacholder; D T Silverman; J K McLaughlin; J S Mandel
Journal:  Am J Epidemiol       Date:  1992-05-01       Impact factor: 4.897

2.  Throat-related quality of life in peritonsillar abscess sufferers: application of the adult tonsil outcome inventory.

Authors:  J Powell; E L Powell; K Conroy; C Hopkins; J W Moor; J A Wilson
Journal:  J Laryngol Otol       Date:  2013-11-20       Impact factor: 1.469

3.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  Int J Surg       Date:  2014-07-18       Impact factor: 6.071

4.  Peritonsillar abscess (PTA): clinical characteristics, microbiology, drug exposures and outcomes of a large multicenter cohort survey of 412 patients hospitalized in 13 French university hospitals.

Authors:  D Lepelletier; V Pinaud; P Le Conte; C Bourigault; N Asseray; F Ballereau; J Caillon; C Ferron; C Righini; E Batard; G Potel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-03-04       Impact factor: 3.267

5.  Relationships between the concentrations of prostaglandins and the nonsteroidal antiinflammatory drugs indomethacin, diclofenac, and ibuprofen.

Authors:  George Giagoudakis; Sophia L Markantonis
Journal:  Pharmacotherapy       Date:  2005-01       Impact factor: 4.705

6.  Hospitalization for severe bacterial infections in children after exposure to NSAIDs: a prospective adverse drug reaction reporting study.

Authors:  Sandrine Leroy; Elisabeth Marc; Françoise Bavoux; Jean-Marc Tréluyer; Dominique Gendrel; Gérard Bréart; Gérard Pons; Martin Chalumeau
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

7.  Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella.

Authors:  S M Lesko; K L O'Brien; B Schwartz; R Vezina; A A Mitchell
Journal:  Pediatrics       Date:  2001-05       Impact factor: 7.124

8.  The validity of a sore throat score in family practice.

Authors:  W J McIsaac; V Goel; T To; D E Low
Journal:  CMAJ       Date:  2000-10-03       Impact factor: 8.262

9.  Administration of the non-steroidal anti-inflammatory drug ibuprofen increases macrophage concentrations but reduces necrosis during modified muscle use.

Authors:  E V Cheung; J G Tidball
Journal:  Inflamm Res       Date:  2003-04       Impact factor: 4.575

10.  Epidemiology, clinical history and microbiology of peritonsillar abscess.

Authors:  E Mazur; E Czerwińska; I Korona-Głowniak; A Grochowalska; M Kozioł-Montewka
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-10-17       Impact factor: 3.267

View more
  5 in total

1.  Comparison of needle aspiration versus incision and drainage under local anaesthesia for the initial treatment of peritonsillar abscess.

Authors:  C Mansour; G De Bonnecaze; E Mouchon; A Gallini; S Vergez; E Serrano
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-07-12       Impact factor: 2.503

2.  Peritonsillar abscess is frequently accompanied by sepsis symptoms.

Authors:  Risto Vaikjärv; Reet Mändar; Priit Kasenõmm
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-04-16       Impact factor: 2.503

3.  Editorial: Pathogenesis and host response in the era of modern diagnostics: let's continue the basics.

Authors:  Dennis L Stevens; Amy E Bryant
Journal:  Curr Opin Infect Dis       Date:  2019-06       Impact factor: 4.915

4.  Acute sore throat and Fusobacterium necrophorum in primary healthcare: a systematic review and meta-analysis.

Authors:  Stefan Malmberg; Susanna Petrén; Ronny Gunnarsson; Katarina Hedin; Pär-Daniel Sundvall
Journal:  BMJ Open       Date:  2021-06-04       Impact factor: 2.692

5.  Nonsteroidal Anti-Inflammatory Drugs Impact on the Outcomes of Hospitalized Patients with Clostridium difficile Infection.

Authors:  Harish Patel; Jasbir Makker; Trupti Vakde; Danial Shaikh; Kanthi Badipatla; James Dunne; Nikhitha Mantri; Suresh Kumar Nayudu; Mariela Glandt; Bhavna Balar; Sridhar Chilimuri
Journal:  Clin Exp Gastroenterol       Date:  2019-12-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.